Lantern Pharma (LTRN) Competitors $2.94 -0.14 (-4.55%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends LTRN vs. BTAI, TNXP, PRPH, LPTX, SKYE, TELO, CADL, ADVM, CGEN, and CRDLShould you be buying Lantern Pharma stock or one of its competitors? The main competitors of Lantern Pharma include BioXcel Therapeutics (BTAI), Tonix Pharmaceuticals (TNXP), ProPhase Labs (PRPH), Leap Therapeutics (LPTX), Skye Bioscience (SKYE), Telomir Pharmaceuticals (TELO), Candel Therapeutics (CADL), Adverum Biotechnologies (ADVM), Compugen (CGEN), and Cardiol Therapeutics (CRDL). These companies are all part of the "pharmaceutical products" industry. Lantern Pharma vs. BioXcel Therapeutics Tonix Pharmaceuticals ProPhase Labs Leap Therapeutics Skye Bioscience Telomir Pharmaceuticals Candel Therapeutics Adverum Biotechnologies Compugen Cardiol Therapeutics Lantern Pharma (NASDAQ:LTRN) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends. Does the media favor LTRN or BTAI? In the previous week, Lantern Pharma and Lantern Pharma both had 4 articles in the media. Lantern Pharma's average media sentiment score of 1.00 beat BioXcel Therapeutics' score of 0.25 indicating that Lantern Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantern Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioXcel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation & earnings, LTRN or BTAI? Lantern Pharma has higher earnings, but lower revenue than BioXcel Therapeutics. Lantern Pharma is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLantern PharmaN/AN/A-$15.96M-$1.78-1.65BioXcel Therapeutics$1.38M18.22-$179.05M-$2.16-0.27 Does the MarketBeat Community prefer LTRN or BTAI? BioXcel Therapeutics received 231 more outperform votes than Lantern Pharma when rated by MarketBeat users. However, 75.00% of users gave Lantern Pharma an outperform vote while only 67.50% of users gave BioXcel Therapeutics an outperform vote. CompanyUnderperformOutperformLantern PharmaOutperform Votes1275.00% Underperform Votes425.00% BioXcel TherapeuticsOutperform Votes24367.50% Underperform Votes11732.50% Do institutionals and insiders hold more shares of LTRN or BTAI? 28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are owned by institutional investors. 7.3% of Lantern Pharma shares are owned by company insiders. Comparatively, 28.7% of BioXcel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is LTRN or BTAI more profitable? Lantern Pharma has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -3,119.33%. BioXcel Therapeutics' return on equity of 0.00% beat Lantern Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Lantern PharmaN/A -56.91% -51.17% BioXcel Therapeutics -3,119.33%N/A -105.04% Which has more risk and volatility, LTRN or BTAI? Lantern Pharma has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Do analysts recommend LTRN or BTAI? BioXcel Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 750.34%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe BioXcel Therapeutics is more favorable than Lantern Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00BioXcel Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryBioXcel Therapeutics beats Lantern Pharma on 9 of the 16 factors compared between the two stocks. Ad WealthPressThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…All you have to do is follow this link here Get Lantern Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LTRN vs. The Competition Export to ExcelMetricLantern PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.22M$6.48B$5.05B$8.87BDividend YieldN/A8.12%4.97%4.06%P/E Ratio-1.655.5697.3414.18Price / SalesN/A348.141,218.4289.42Price / CashN/A22.1533.5132.79Price / Book1.197.885.805.12Net Income-$15.96M$153.61M$119.07M$225.99M7 Day Performance-15.76%-2.00%-1.83%-1.32%1 Month Performance-12.50%-7.47%-3.64%0.60%1 Year Performance-26.13%31.80%31.62%26.23% Lantern Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LTRNLantern Pharma1.5019 of 5 stars$2.94-4.5%N/A-27.0%$33.22MN/A-1.6520Positive NewsGap DownBTAIBioXcel Therapeutics4.5124 of 5 stars$0.59-1.7%$5.00+750.3%-84.6%$25.14M$1.38M-0.2790Gap DownTNXPTonix Pharmaceuticals2.9619 of 5 stars$0.19+18.8%$53.50+28,057.9%-98.8%$22.33M$7.77M0.00103Analyst ForecastGap UpHigh Trading VolumePRPHProPhase Labs3.242 of 5 stars$0.77+1.3%$11.00+1,337.9%-82.8%$18.14M$44.38M0.00130LPTXLeap Therapeutics2.3936 of 5 stars$2.59-4.1%$7.50+189.6%+25.1%$69.12M$1.50M0.0040Positive NewsSKYESkye Bioscience1.2808 of 5 stars$4.28-1.4%$18.67+336.1%+152.9%$131.67MN/A0.0011Insider TradeTELOTelomir PharmaceuticalsN/A$4.20-5.4%N/AN/A$131.47MN/A0.001CADLCandel Therapeutics1.8165 of 5 stars$3.98-0.3%$11.00+176.4%+347.1%$129.25M$120,000.00-2.3060Analyst ForecastAnalyst RevisionNews CoverageADVMAdverum Biotechnologies4.1701 of 5 stars$6.17-1.3%$27.83+351.1%-32.5%$128.34M$3.60M-1.03190Analyst ForecastShort Interest ↓CGENCompugen2.7226 of 5 stars$1.43-0.7%$4.00+179.7%+121.5%$127.61M$59.85M71.5068CRDLCardiol Therapeutics2.7365 of 5 stars$1.56-5.5%$8.75+460.9%+81.1%$127.30M$60,000.00-4.0020Analyst ForecastAnalyst RevisionNews Coverage Related Companies and Tools Related Companies BTAI Alternatives TNXP Alternatives PRPH Alternatives LPTX Alternatives SKYE Alternatives TELO Alternatives CADL Alternatives ADVM Alternatives CGEN Alternatives CRDL Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LTRN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantern Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
